The CYP19 TTTA Repeat Polymorphism Is Related to the Prognosis of Premenopausal Stage I–II and Operable Stage III Breast Cancers

Abstract

After completing this course, the reader should be able to:1. Describe why premenopausal women with the long allele of the CYP19 TTTA repeat polymorphism have a greater survival rate and may not gain benefit from adjuvant chemotherapy.2. Assess whether we need to revisit the routine use of adjuvant chemotherapy in high-risk premenopausal patients with the long allele of the CYP19 polymorphism.3. Explain why further validation in a randomized study with a large sample size is needed to determine whether the CYP19 TTTA repeat polymorphism can serve as a predictor in hormone receptor-positive premenopausal patients.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTPurpose. Given the critical role of the CYP19 gene, encoding aromatase, in estrogen synthesis and the association of the estrogen level with its TTTA repeat polymorphism, the potential influence of this polymorphism on breast cancer survival, and hence management, deserves further study.

Polymorphism of Cytochrome P450, Superfamily19, Polypeptide 1 Gene and Related to Aromatase Enzyme Activity in Acromegaly Iraqi Patients

“…Many prior studies from Korean people [17], Japanese people [18], and Caucasian people [19], all of that showed no significant correlation of CYP19 gene polymorphisms with the hazard of chocolate cysts or endometriosis. The study by Hirose et al, [20] showed that in estrogen biosynthesis, the genetic polymorphisms (CYP19A1) are as well expected to affect the degradation or synthesis of estrogen, and then, lead to increase the breast cancer risk at codon 39 [21,22], the (rs2236722) polymorphism is created by the substitution of amino acids (Trp) with (Arg), while another study showed the Japanese women with the presence of these different alleles (Arg) lead to significantly decreased the developing of the breast cancer risk [23]. In a survey by Leporati et al, the authors deal with the male patients with breast cancer and acromegaly.…”

EGFRL858R Mutation and Polymorphisms of Genes Related to Estrogen Biosynthesis and Metabolism in Never-Smoking Female Lung Adenocarcinoma Patients

“…Furthermore, an aromatase inhibitor was reported to suppress cell growth and aromatase activity in lung A549 cells in vitro (30). A (TTTA) n repeat polymorphism in intron 4 of CYP19A1 was found to be associated with the risk of breast cancer (32) and the prognosis of patients affected by premenopausal breast cancer (20). Women with one 7-repeat allele (S allele) had lower plasma levels of estroneto-androstenedione ratio (32).…”

“…The genotypes of ERa, rs2234693, as "C/C and T/C" vs. "T/T"; of COMT, rs4680, as "A/A and G/A" vs. "G/G," and of CYP17, rs743572, were grouped as "C/C" vs. "T/T and T/C." This grouping scheme has been commonly used in previous studies (20)(21)(22).…”

Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy

“…Breast cancer staging was conducted according to the American Joint Committee on Cancer (AJCC) criteria (the 6th Ed.). Patients' demographic information was collected from a genetic epidemiology study on the association between selected genetic polymorphisms and breast cancer in 482 patients, which was carried out at the same hospital (Huang et al, 2008). To avoid bias caused by the uncertain treatment effects of tamoxifen in tumors with weak ER and/or PR expression, 43 patients who did not receive adjuvant tamoxifen were excluded.…”